Selvedge Venture

San Francisco, California
Firm Location:San Francisco, California • London • Singapore • Greece • Cambridge, United Kingdom
Selvedge Venture Team
Photo of Serge Faguet, Venture Partner at Selvedge Venture
Serge Faguet
Selvedge Venture·Venture Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in San Francisco (CA)
Investors in Material Science (Seed), Investors in Medical Devices (Seed), Investors in SMB Software (Seed), Investors in AI (Series B), Investors in Pharmaceuticals (Seed), Investors in Insurance (Seed), Investors in BioTech (Series B), Investors in E-commerce (Series B), Investors in E-commerce (Series A), Investors in Medical Devices (Series B), Investors in Insurance (Series B), Investors in Medical Devices (Series A), Investors in Enterprise (Series B), Investors in Material Science (Series B), Investors in BioTech (Seed), Investors in Material Science (Series A), Investors in Insurance (Series A), Investors in Pharmaceuticals (Series B), Investors in SMB Software (Series B), Investors in SMB Software (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in AI (Seed), Investors in Investors who were founders (Other Lists), Investors in SaaS (Series B), Investors in AI (Series A), Investors in E-commerce (Seed), Investors in BioTech (Seed), Investors in E-commerce (Seed), Investors in Enterprise (Series A), Investors in Enterprise (Seed), Investors in Medical Devices (Seed), Investors in Insurance (Seed), Investors in SaaS (Seed), Investors in SMB Software (Seed), Investors in Material Science (Seed), Investors in Pharmaceuticals (Seed), Investors in San Francisco Bay Area (Other Lists), Investors in AI (Series A), Investors in BioTech (Series A), Investors in E-commerce (Series A), Investors in Enterprise (Series A), Investors in Insurance (Series A), Investors in Material Science (Series A), Investors in Medical Devices (Series A), Investors in SaaS (Series A), Investors in SMB Software (Series A), Investors in Pharmaceuticals (Series A), Investors in AI (Series B), Investors in BioTech (Series B), Investors in E-commerce (Series B), Investors in Enterprise (Series B), Investors in Insurance (Series B), Investors in Material Science (Series B), Investors in Pharmaceuticals (Series B), Investors in Medical Devices (Series B), Investors in SMB Software (Series B), Investors in SaaS (Series B), Investors in SaaS (Series A), Investors in AI (Seed), Investors in SaaS (Seed), Investors in Enterprise (Seed)
Photo of Emil Hewage, Venture Partner at Selvedge Venture
Emil Hewage
Selvedge Venture·Venture Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Cambridge (United Kingdom)
Investors in Medical Devices (Seed), Investors in ClimateTech/CleanTech (Series A), Investors in ClimateTech/CleanTech (Seed), Investors in Medical Devices (Series A), Investors in AI (Seed), Investors in AI (Series A), Investors in DeepTech (Series A), Investors in DeepTech (Seed), Investors in Medical Devices (Pre-seed), Investors in DeepTech (Pre-seed), Investors in ClimateTech/CleanTech (Pre-seed), Investors in AI (Pre-seed), Investors in FinTech (Pre-seed), Investors in FinTech (Series A), Investors in FinTech (Seed)
Photo of Kai Sing Hii, Analyst at Selvedge Venture
Kai Sing Hii
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Singapore
Photo of Angelos Spiliopoulos, Analyst at Selvedge Venture
Angelos Spiliopoulos
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Greece
Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series A), Investors in Pharmaceuticals (Pre-seed), Investors in BioTech (Pre-seed)
Photo of Robert Thong, General Partner at Selvedge Venture
Robert Thong
Selvedge Venture·General Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in London
Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in Health IT (Series A), Investors in BioTech (Seed), Investors in Enterprise (Seed), Investors in Enterprise (Series A), Investors in Health IT (Seed), Investors in Health & Hospital Services (Series A), Investors in Pharmaceuticals (Seed), Investors in Health & Hospital Services (Seed), Investors in BioTech (Series A), Investors in Enterprise (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Pharmaceuticals (Series A), Investors in London (Other Lists), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Enterprise Applications (Series A), Investors in Enterprise Applications (Seed), Investors in Enterprise Applications (Series A), Investors in Enterprise Applications (Seed), Investors in Pharmaceuticals (Pre-seed), Investors in Health IT (Pre-seed), Investors in Enterprise Applications (Pre-seed), Investors in Digital Health (Pre-seed), Investors in BioTech (Pre-seed), Investors in Health & Hospital Services (Pre-seed), Investors in Enterprise (Pre-seed), Investors in Enterprise (Pre-seed), Investors in Health IT (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in Enterprise Applications (Pre-seed), Investors in BioTech (Pre-seed), Investors in Health & Hospital Services (Pre-seed), Investors in Digital Health (Pre-seed), Investors in Health IT (Seed), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed), Investors in Enterprise (Seed)